{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:29Z","timestamp":1787027369402,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Respiratory syncytial virus (RSV) is a leading cause of infant hospitalization globally. On September 1, 2024, England introduced the bivalent RSVpreF vaccine for maternal immunization following trial evidence of safety and efficacy. However, real-world data on uptake, safety and effectiveness remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a retrospective audit using routinely collected electronic health record data from Oxford University Hospitals NHS Foundation Trust. All live births between September 1 and October 31, 2024, were included. Maternal RSV vaccination status, demographic factors and perinatal outcomes were analyzed. RSV-related hospitalizations were tracked from November 1, 2024, to March 12, 2025. Vaccine effectiveness (VE) was calculated as 1 \u2212 (risk in vaccinated\/risk in unvaccinated) \u00d7 100.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 1057 live births, 341 mothers (32.3%) received RSVpreF vaccination during pregnancy. Uptake was higher in older and primiparous mothers and strongly associated with receipt of pertussis vaccine (41.3% vs. 11.6%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). No differences were observed in gestational age or birthweight between groups. RSV-confirmed hospitalization occurred in 2 of 285 infants born &gt;14 days post-vaccination and in 36 of 772 unvaccinated infants, yielding a crude VE of 78.3% (95% confidence interval, 9.1\u201394.8) in infants &lt;6 months of age. VE against bronchiolitis-coded admissions was 56.4% (95% confidence interval, 13.1\u201378.2).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Maternal RSV vaccination was associated with substantial protection against infant RSV hospitalization during the first UK season of implementation. Uptake improved over time but remained relatively low. Early safety data are reassuring. Continued surveillance and larger multisite evaluations are needed to support national program monitoring and integration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005368","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:00:21Z","timestamp":1787025621000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Uptake, Safety and Effectiveness of the Maternal RSV Vaccine (RSVpreF) Against Infant Bronchiolitis: Preliminary Real-World Evidence"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9912-8394","authenticated-orcid":false,"given":"Genevieve","family":"Haddock","sequence":"first","affiliation":[{"name":"Department of Paediatrics, Oxford University Hospitals, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Oxford University Hospitals, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Oxford University Hospitals, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Vakis","sequence":"additional","affiliation":[{"name":"Oxford University Medical School, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon B.","family":"Drysdale","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom"},{"name":"NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"R1-20260818","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"R2-20260818","doi-asserted-by":"crossref","first-page":"e009337","DOI":"10.1136\/bmjopen-2015-009337","article-title":"Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK.","volume":"6","author":"Taylor","year":"2016","journal-title":"BMJ Open"},{"key":"R3-20260818","first-page":"e77176","article-title":"Safety and efficacy of vaccines during pregnancy: a systematic review.","volume":"17","author":"Chittajallu","year":"2025","journal-title":"Cureus"},{"key":"R4-20260818","doi-asserted-by":"crossref","first-page":"638871","DOI":"10.3389\/fped.2021.638871","article-title":"The protective role of maternal immunization in early life.","volume":"9","author":"Cinicola","year":"2021","journal-title":"Front Pediatr"},{"key":"R5-20260818","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants.","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"R6-20260818","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2352-4642(25)00155-5","article-title":"Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants: results of a multi-centre, test-negative study.","volume":"9","author":"Williams","year":"2025","journal-title":"Lancet Child Adolesc Health"},{"key":"R7-20260818","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S1473-3099(25)00156-2","article-title":"Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants in Argentina (BERNI study): a multicentre, retrospective, test-negative, case\u2013control study.","volume":"25","author":"P\u00e9rez Marc","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"R8-20260818","first-page":"e202510741","article-title":"Evaluation of the effectiveness of the respiratory syncytial virus vaccine in children under 6 months of age in C\u00f3rdoba, Argentina.","volume":"123","author":"Scruzzi","year":"2025","journal-title":"Arch Argent Pediatr"},{"key":"R9-20260818","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/INF.0000000000004878","article-title":"Maternal immunization with RSVpreF vaccine: effectiveness in preventing respiratory syncytial virus-associated hospitalizations in infants under 6 months in Argentina: multicenter case-control study.","volume":"44","author":"Gentile","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20260818","first-page":"362","article-title":"Vaccine effectiveness of the maternal RSVpre-F vaccine against severe disease in infants in Scotland, UK: national population-based case-control and cohort analyses [preprint].","volume":"26","author":"McLachlan","year":"2025","journal-title":"medRxiv"},{"key":"R11-20260818","doi-asserted-by":"crossref","first-page":"e2419268","DOI":"10.1001\/jamanetworkopen.2024.19268","article-title":"Nonadjuvanted bivalent respiratory syncytial virus vaccination and perinatal outcomes.","volume":"7","author":"Son","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R14-20260818","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1473-3099(25)00060-X","article-title":"Maternal views on RSV vaccination during the first season of implementation in England and Scotland.","volume":"25","author":"Williams","year":"2025","journal-title":"Lancet Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005368","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:00:23Z","timestamp":1787025623000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005368","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}